Komori
Astellas Pharma (4503) · RiskRestated

Credit Risk of Business Counterparties, Financial Institutions and Others

First written in FY2019. 8 of 9 entries say "Restated". Latest entry: FY2024-Q3.

9entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2019 – FY2024-Q32019: 120192020: 220202021: 320212022: 120222023: 120232024: 1
Same theme, other companies
Credit, Market Price Volatility, and Liquidity Risk Management for Financial AssetsA theme 55 companies write about · 52 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2020: 9 of 34 companies on the "Worse" side.

30 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 55 companies compared. The sentences above are computed from all 55.
Full recordFilings, disclosures and news, newest first
  1. FY2024-Q3RestatedAnnual report

    「During the nine-month cumulative period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」

    取引先・金融機関等の信用リスクを含む既存の事業等のリスクについて、重要な変更がないと再確認している。
  2. FY2024-Q1RestatedAnnual report

    「During the three-month cumulative period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」

    取引先・金融機関等の信用リスクを含む既存の事業等のリスクについて、重要な変更がないと再確認している。
  3. FY2022-Q3RestatedAnnual report

    「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    取引先・金融機関等の信用リスクを含む既存の事業等のリスクについて、重要な変更がないと再確認している。
  4. FY2022-Q2RestatedAnnual report

    「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    取引先・金融機関等の信用リスクを含む既存の事業等のリスクについて、重要な変更がないと再確認している。
  5. FY2022-Q1RestatedAnnual report

    「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    取引先・金融機関等の信用リスクを含む既存の事業等のリスクについて、重要な変更がないと再確認している。quantified/materializedは本引用上は該当しない。
  6. FY2021-Q3RestatedAnnual report

    「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    取引先・金融機関等の信用リスクを含む既存の事業等のリスクについて、重要な変更がないと再確認している。
  7. FY2021-Q1RestatedAnnual report

    「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    取引先・金融機関等の信用リスクを含む既存の事業等のリスクについて、重要な変更がないと再確認している。
  8. FY2020-Q3RestatedAnnual report

    「There were no newly arising business or other risks during the cumulative third-quarter period, and no material changes to the business or other risks described in the securities report for the previous fiscal year.」

    取引先・金融機関等の信用リスクを含む既存の事業等のリスクについて、重要な変更がないと再確認している。
  9. FY2019First statedAnnual report

    「当社グループは、事業活動を行うにあたり、信用リスク、流動性リスク及び為替リスク等の財務上のリスクに晒されており、これらのリスクを低減するために、一定の方針等に基づきリスク管理を行っています。」

    売掛金、保有有価証券、預金及びデリバティブ取引相手に関する信用リスクを明示し、信用格付け基準等による管理を記載している。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Astellas Pharma's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.